AMED — Amedisys Cashflow Statement
0.000.00%
Last trade - 00:00- $3.32bn
- $3.39bn
- $2.35bn
- 96
- 63
- 91
- 97
Annual cashflow statement for Amedisys, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 185 | 210 | 118 | -10.9 | 38.2 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 36.2 | -6.1 | 26.3 | 133 | 75.7 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 26.2 | -131 | -105 | -63.2 | 39.9 |
| Change in Accounts Receivable | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 289 | 189 | 133 | 137 | 222 |
| Capital Expenditures | -5.33 | -6.72 | -7.21 | -12.7 | -7.37 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -282 | -275 | -87.3 | 47.8 | -0.991 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -287 | -282 | -94.5 | 35.1 | -8.36 |
| Financing Cash Flow Items | 4.38 | -81.2 | -5.94 | -14.2 | -11.9 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -15 | 55.1 | -30.4 | -87.5 | -48.9 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -13.1 | -37.6 | 8.36 | 84.7 | 164 |